Payment overview · 2025
General Payments
$1,581.29
72 reported records · 19 companies
Healthcare provider profile · identity verified
Boris Mazurov, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1023119039
Verified facts
What the public records show
CMS Open Payments records show Boris Mazurov, M.D. received $1,581.29 in general payments during 2025 across 72 reported records.
ABBVIE INC. accounted for 14.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Prolia, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 215 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 272 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 460 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 272 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 460 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $233.29 | 14.8% | 13 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $208.30 | 13.2% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $180.66 | 11.4% | 8 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $136.54 | 8.6% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $111.60 | 7.1% | 5 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $99.28 | 6.3% | 5 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$94.09 | 6.0% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $91.34 | 5.8% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $84.31 | 5.3% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $77.70 | 4.9% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $72.79 | 4.6% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $55.13 | 3.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $25.43 | 1.6% | 1 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $23.85 | 1.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.22 | 1.4% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $18.59 | 1.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.65 | 1.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $14.71 | 0.9% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $13.81 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,581.29 | 72 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $253.75 | 11 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $208.30 | 8 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $130.57 | 9 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $97.05 | 8 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $94.09 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $91.34 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $77.70 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $72.79 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $64.49 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $64.49 | 3 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $62.50 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $55.13 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $38.51 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $38.51 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $36.78 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $25.43 | 1 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $23.85 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $13.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 64 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 460 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 69 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 272 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 215 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 55 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 93 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
64 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
215 | 33 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
183 | 22 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
55 | 43 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
69 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
272 | 42 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
460 | 58 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
93 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
272 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
81 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
460 | 58 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1259 | 200 |
| Amlodipine Besylate | Amlodipine Besylate | 1118 | 177 |
| Losartan Potassium | Losartan Potassium | 856 | 129 |
| Atorvastatin Calcium | Atorvastatin Calcium | 853 | 139 |
| Metoprolol Succinate | Metoprolol Succinate | 807 | 117 |
| Metformin Hcl | Metformin Hcl | 500 | 88 |
| Eliquis | Apixaban | 460 | 58 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 369 | 62 |
| Carvedilol | Carvedilol | 364 | 52 |
| Vascepa | Icosapent Ethyl | 357 | 61 |
| Alendronate Sodium | Alendronate Sodium | 337 | 60 |
| Levothyroxine Sodium | Levothyroxine Sodium | 337 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 322 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 318 | 49 |
| Omeprazole | Omeprazole | 301 | 56 |
| Jardiance | Empagliflozin | 272 | 42 |
| Atenolol | Atenolol | 256 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 256 | 40 |
| Dexlansoprazole Dr | Dexlansoprazole | 255 | 49 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 251 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 218 | 39 |
| Linzess | Linaclotide | 215 | 33 |
| Ezetimibe | Ezetimibe | 210 | 42 |
| Allopurinol | Allopurinol | 196 | 32 |
| Synthroid | Levothyroxine Sodium | 183 | 22 |
| Gabapentin | Gabapentin | 173 | 39 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 165 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 164 | 55 |
| Jentadueto | Linagliptin/Metformin Hcl | 153 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 148 | 19 |
| Enalapril Maleate | Enalapril Maleate | 144 | 22 |
| Icosapent Ethyl | Icosapent Ethyl | 142 | 37 |
| Memantine Hcl Er | Memantine Hcl | 138 | 23 |
| Glimepiride | Glimepiride | 130 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 126 | 52 |
| Simvastatin | Simvastatin | 126 | 20 |
| Tradjenta | Linagliptin | 125 | 18 |
| Myrbetriq | Mirabegron | 122 | 19 |
| Zenpep | Lipase/Protease/Amylase | 122 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 116 | 33 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 115 | 29 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 110 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 105 | 16 |
| Famotidine | Famotidine | 104 | 26 |
| Valsartan | Valsartan | 104 | 16 |
| Furosemide | Furosemide | 99 | 24 |
| Nebivolol Hcl | Nebivolol Hcl | 97 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 93 | 17 |
| Lisinopril | Lisinopril | 91 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 84 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 83 | 11 |
| Entresto | Sacubitril/Valsartan | 81 | 17 |
| Finasteride | Finasteride | 81 | suppressed |
| Nifedipine Er | Nifedipine | 80 | 13 |
| Warfarin Sodium | Warfarin Sodium | 75 | suppressed |
| Fenofibrate | Fenofibrate | 73 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 72 | 12 |
| Farxiga | Dapagliflozin Propanediol | 69 | 15 |
| Repatha Sureclick | Evolocumab | 69 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 68 | 18 |
| Dutasteride | Dutasteride | 66 | suppressed |
| Creon | Lipase/Protease/Amylase | 64 | 21 |
| Hydrocortisone | Hydrocortisone | 63 | 11 |
| Metformin Hcl Er | Metformin Hcl | 63 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 14 |
| Cilostazol | Cilostazol | 60 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 60 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 55 | 25 |
| Prolia | Denosumab | 55 | 43 |
| Trulicity | Dulaglutide | 55 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 54 | suppressed |
| Procto-Med Hc | Hydrocortisone | 54 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 53 | 12 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 51 | suppressed |
| Telmisartan | Telmisartan | 50 | suppressed |
| Januvia | Sitagliptin Phosphate | 49 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 48 | suppressed |
| Azithromycin | Azithromycin | 47 | 43 |
| Ranolazine Er | Ranolazine | 47 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 46 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 44 | 13 |
| Edarbi | Azilsartan Medoxomil | 44 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 44 | 18 |
| Trintellix | Vortioxetine Hydrobromide | 44 | suppressed |
| Dexilant | Dexlansoprazole | 43 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 43 | 13 |
| Donepezil Hcl | Donepezil Hcl | 41 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 40 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 38 | suppressed |
| Irbesartan | Irbesartan | 36 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 36 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Febuxostat | Febuxostat | 34 | suppressed |
| Lidocaine | Lidocaine | 33 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 33 | 17 |
| Mometasone Furoate | Mometasone Furoate | 31 | 20 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 30 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 30 | suppressed |
| Clonidine | Clonidine | 29 | suppressed |
| Proctozone-Hc | Hydrocortisone | 29 | suppressed |
| Meloxicam | Meloxicam | 28 | 11 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | 14 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 22 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 21 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 21 | suppressed |
| Trulance | Plecanatide | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | 12 |
| Praluent Pen | Alirocumab | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 19 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 16 |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 13 |
| Gemtesa | Vibegron | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 12 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Acarbose | Acarbose | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,581.29 · 72 records | ABBVIE INC. | CAMZYOS, CREON, CeQur Simplicity, ELIQUIS, EVENITY, FARXIGA, GVOKE HYPOPEN, IBSRELA, JARDIANCE, Kerendia, Korlym, LEQVIO, LINZESS, MINIMED 780G, MOUNJARO, NEXLETOL, NP Thyroid 60, NURTEC ODT, OTEZLA, PROLIA, RECORLEV, REPATHA, TRELEGY ELLIPTA, Yorvipath, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error